Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.

CDI and SDI In TRANSFORMS, Kaplan–Meier time-to-event analysis over 8 years showed a trend toward a greater cumulative probability of achieving CDI with continuous fingolimod than with IFNβ-1a/fingolimod ( Figure 2(a) ).

also in 53,322 other papers